Uremia Therapy

1. Front Matter

   Pages I-XIII

   PDF

2. Professor Nils Alwall — In Memoriam

   1. Professor Nils Alwall — In Memoriam

      • H. Klinkmann, C. M. Kjellstrand

      Pages 1-2

3. The First 25 Years

   1. Front Matter

      Pages 3-3

      PDF

   2. Seattle Hemodialysis Experience: The First 25 Years

      • B. H. Scribner, S. Ahmad, A. L. Babb, J. J. Cole

      Pages 5-27

   3. Realization of Missed Opportunities

      • W. J. Kolff

      Pages 28-50

4. Therapies

   1. Front Matter

      Pages 51-51

      PDF

   2. Will CAPD Continue for Another Decade?

      • J. F. Maher

      Pages 53-62

   3. Therapeutic Plasmapheresis: The Road Not Yet Taken

      • H. J. Gurland

      Pages 63-73

   4. Alternative Therapies: Achievement Versus Expectations

      • L. W. Henderson

      Pages 74-89

   5. Transplantation: Wherefore So Slight an Impact?

      • P. A. Keown, C. R. Stiller

      Pages 90-97

   6. Living To See the Twenty-First Century with End Stage Renal Disease: One Patient’s Viewpoint

      • A. P. Lundin

      Pages 98-108

5. Technology

   1. Front Matter

      Pages 109-109

      PDF

   2. Evolution of Membrane Technology: Possibilities and Consequences

      • G. von Sengbusch, H. D. Lemke, J. Vienken

      Pages 111-124

   3. Clinical Relevance of Biocompatibility — The Material Cannot Be Divorced from the Device

      • H. Klinkmann, D. Falkenhagen, J. M. Courtney

      Pages 125-140

   4. Unrealized Impact of Kinetic Modeling

      • P. C. Farrell

      Pages 141-153

6. Nephrological Issues

   1. Front Matter

      Pages 155-155

      PDF

   2. Influence of the Renal Biopsy

      • R. H. Heptinstall

      Pages 157-163

   3. Immunological Aspects of Renal Medicine

      • D. K. Peters

      Pages 164-169

   4. Impact of Artificial Organs on Modern Medicine

      • G. E. Schreiner

      Pages 170-184

7. Contemporary Survey

   1. Front Matter

      Pages 185-185

      PDF

Little doubt exists that hemodialysis represents a major event in the course of modern medicine. Technologies which had previously been considered heroic or appropriate only in intensive care settings became so commonplace as to be conducted at home or in limited-care settings. The chronic anephric mammal, absent from the Darwinian evolution, was created and grew rapidly in number to a total population base of nearly one-quarter million. The physiology of this new "species" was defined, and methods of managing its pathophysiologies were developed and refined. A subspeciality of medicine and a multi-billion dollar industry were born. And the requisite dedication of resources, effort, and man­ power raised hitherto unheard questions about the limits to growth of high­ technology on medicine. At Rottach-Egern, a small village nestled in the foothills of the Bavarian Alps, many (perhaps most) of the founders and pioneers of renal dialysis assembled in June of 1986 in order to reflect upon the progress and problems of the first 25 years of hemodialysis and to establish vectors and directions for the coming quarter century. Sadly missing were Drs. Nils Alwall and John Merrill who died during the years this conference was in planning. But present and active were Drs. Kolff and Scribner, whose breakthrough contributions represent the cardi­ nal landmarks of the development of contemporary End Stage Renal Disease therapy.

• dialysis
• hemodialysis
• intensive care
• pathophysiology
• physiology
• transplantation

• Klinikum Großhadern Medizinische Klinik I Nephrologische Abteilung, Ludwigs-Maximilians-Universität München, München 70, Germany

  Hans Jürgen Gurland

Policies and ethics